Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “L-DOPA Group”

19 trials

Showing 19 of 19 results

Testing effectiveness (Phase 2)Study completedNCT01474421
What this trial is testing

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Who this might be right for
DyskinesiasDrug-induced
Novartis Pharmaceuticals 71
Testing effectiveness (Phase 2)Study completedNCT00314288
What this trial is testing

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Who this might be right for
Parkinson's DiseaseDyskinesia
EMD Serono 360
Large-scale testing (Phase 3)Study completedNCT00363727
What this trial is testing

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

Who this might be right for
Parkinson's DiseaseParkinson DiseaseDyskinesias
GlaxoSmithKline 209
Post-approval studies (Phase 4)Study completedNCT01951105
What this trial is testing

Effect of L-dopa In Subacute Back Pain Population

Who this might be right for
Sub-acute Back Pain
Northwestern University 72
Large-scale testing (Phase 3)Study completedNCT04978597
What this trial is testing

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Who this might be right for
Parkinson
Bial - Portela C S.A. 410
Testing effectiveness (Phase 2)Study completedNCT01602549
What this trial is testing

Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

Who this might be right for
Gastroparesis
GlaxoSmithKline 58
Large-scale testing (Phase 3)Study completedNCT00381472
What this trial is testing

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

Who this might be right for
Parkinson Disease
GlaxoSmithKline 393
Testing effectiveness (Phase 2)Study completedNCT00582673
What this trial is testing

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

Who this might be right for
Parkinson's Disease
Novartis 31
Large-scale testing (Phase 3)Study completedNCT01154166
What this trial is testing

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Who this might be right for
Parkinson Disease
GlaxoSmithKline 347
Post-approval studies (Phase 4)Study completedNCT04821687
What this trial is testing

Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Who this might be right for
Parkinson Disease
SK Chemicals Co., Ltd. 169
Large-scale testing (Phase 3)Study completedNCT00331149
What this trial is testing

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

Who this might be right for
Parkinson Disease
GlaxoSmithKline 343
Large-scale testing (Phase 3)Study completedNCT01628926
What this trial is testing

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

Who this might be right for
Parkinson's Disease
Otsuka Pharmaceutical Co., Ltd. 420
Testing effectiveness (Phase 2)Study completedNCT00888004
What this trial is testing

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

Who this might be right for
Parkinson's DiseaseL-dopa Induced Dyskinesia
Novartis 28
Large-scale testing (Phase 3)Study completedNCT00466167
What this trial is testing

Pivotal Study in Advanced Parkinsons Disease Patients

Who this might be right for
Parkinson Disease
Boehringer Ingelheim 517
Testing effectiveness (Phase 2)Study completedNCT01113320
What this trial is testing

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

Who this might be right for
Parkinson's Disease
Newron Pharmaceuticals SPA 26
Post-approval studies (Phase 4)Study completedNCT03521635
What this trial is testing

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

Who this might be right for
Parkinson Disease
Boehringer Ingelheim 98
Large-scale testing (Phase 3)Study completedNCT00560508
What this trial is testing

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Who this might be right for
Parkinson Disease
Boehringer Ingelheim 112
Not applicableStudy completedNCT03891095
What this trial is testing

Oxytocin and Dopamine's Effect on Vicarious Optimism

Who this might be right for
Oxytocin GroupL-DOPA GroupPlacebo Group
Beijing Normal University 156
Large-scale testing (Phase 3)Study completedNCT00134251
What this trial is testing

Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease

Who this might be right for
Parkinson's Disease
Solvay Pharmaceuticals

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation